Microbix & Ulisse Biomed Collaborate on HPV Controls & Assays
10 nov. 2023 07h00 HE | Microbix Biosystems Inc.
Microbix secures a new European collaborator, Ulisse Biomed, in relation to HPV testing and cervical cancer screening.
Microbix QAPs Supporting HPV Testing in Ireland
27 oct. 2023 07h00 HE | Microbix Biosystems Inc.
MISSISSAUGA, Ontario, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its...
Point of Care Diagnostics Market to Hit 12.7% CAGR with Glucose Monitoring Products Driving Growth During 2021–2028 | The Insight Partners
26 oct. 2023 07h55 HE | The Insight Partners
Pune, India, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Point-of-care testing (POCT) is essential for the rapid detection of analytes near to the patient, which facilitates in disease diagnosis, monitoring,...
Antibody Drug Conjugates Market Revenue to Hit $29.6 Billion, Globally, by 2030 – Exclusive Study by The Insight Partners
09 oct. 2023 08h04 HE | The Insight Partners
Pune, India, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Antibody drug conjugates (ADC) are one of the fastest growing anticancer drugs. It is typically composed of a monoclonal antibody (mAbs) covalently...
Infectious Disease Diagnostics Market to Hit $37.94 Billion, Globally, by 2028 – Exclusive Report by The Insight Partners
20 sept. 2023 10h22 HE | The Insight Partners
Pune, India., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Tuberculosis (TB) is the 13th most significant cause of mortality globally and the second leading infectious disease after COVID-19, according to the...
AHCC Quality of Life
Association Sheds Light on Latest Advances of AHCC During Sexual Health Month
13 sept. 2023 08h30 HE | AHCC Association
NEW YORK, Sept. 13, 2023 (GLOBE NEWSWIRE) -- With Sexual Health Month in full swing this September, the AHCC Association is urging individuals to enhance their understanding of sexual health,...
Sabin Vaccine Institute Logo.png
Sabin Vaccine Institute Leads Public and Private Sector Fight to Prevent HPV and End Cervical Cancer with Global HPV Consortium Launch in Kuala Lumpur
04 sept. 2023 18h00 HE | Sabin Vaccine Institute
KUALA LUMPUR, Malaysia, Sept. 05, 2023 (GLOBE NEWSWIRE) -- The Global HPV Consortium, a worldwide public and private collaboration focused on accelerating prevention of Human Papillomavirus (HPV) and...
PDS Biotech Logo.png
PDS Biotech to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023
20 juin 2023 08h00 HE | PDS Biotechnology Corporation
FLORHAM PARK, N.J., June 20, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corp. (NASDAQ: PDSB), a clinical-stage company developing a growing pipeline of targeted immunotherapies for cancer and...
PDS Biotech Logo.png
PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the VERSATILE-002 Trial Evaluating PDS0101 and KEYTRUDA® in Head and Neck Cancer
14 juin 2023 08h00 HE | PDS Biotechnology Corporation
14 patients in the immune checkpoint inhibitor naïve arm of VERSATILE-002 have experienced either a complete response or partial response on two consecutive scans, thus constituting a confirmed...
PDS Biotech Logo.png
PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients
25 mai 2023 17h00 HE | PDS Biotechnology Corporation
Interim data being presented at ASCO 2023 Annual Meeting Demonstrated median progression-free survival (PFS) of 10.4 months Demonstrated 12-month overall survival (OS) rate of 87.1%A disease control...